Topic: clinical trial data
The analyses provide further evidence of the effect the TORC1 inhibitor has on the incidence of infection in high-risk elderly patients.
Chronocort was no better at controlling sex hormones than conventional glucocorticoid doses, sending Diurnal’s stock into a downward spiral.
The interim readout showed that two-fifths of infants who received PTC and Roche’s oral SMA drug were sitting eight months after starting treatment.
The readout linked the ALAS1-targeted RNAi to a drop in urinary ALA, a biomarker Alnylam and the FDA think may predict clinical benefit.
The results tee Aldeyra up to move the aldehyde-binding small molecule into phase 3 next year.
The biotech changed its plans because its phase 3 overall response rate data “were not sufficiently mature to conduct the analysis.”
The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.
The first-in-human clinical trial suggested that AST-008 is safe, tolerable and boosts cytokine levels.
The results hint at the efficacy of the antibody Fc fragment in primary immune thrombocytopenia, leading Argenx to commit to running a phase 3.
Bone wants to move the therapy into phase 2b, but that plan is on hold as it adopts an industrialized manufacturing process.